American Century Companies Inc. Purchases 4,698 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

American Century Companies Inc. grew its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 99.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,444 shares of the medical instruments supplier’s stock after purchasing an additional 4,698 shares during the period. American Century Companies Inc. owned about 0.17% of Mesa Laboratories worth $1,245,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. FMR LLC raised its stake in Mesa Laboratories by 34.1% in the 3rd quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 100 shares during the period. Amundi raised its position in shares of Mesa Laboratories by 81.6% in the fourth quarter. Amundi now owns 661 shares of the medical instruments supplier’s stock valued at $91,000 after purchasing an additional 297 shares during the period. Captrust Financial Advisors purchased a new stake in shares of Mesa Laboratories during the 3rd quarter valued at approximately $207,000. Berry Wealth Group LP boosted its holdings in Mesa Laboratories by 5.3% in the 4th quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier’s stock worth $219,000 after buying an additional 83 shares during the period. Finally, Pacer Advisors Inc. grew its stake in Mesa Laboratories by 4.3% in the 4th quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier’s stock valued at $231,000 after buying an additional 73 shares in the last quarter. 90.60% of the stock is owned by institutional investors.

Mesa Laboratories Stock Performance

NASDAQ:MLAB opened at $109.86 on Friday. The business’s fifty day moving average is $130.68 and its 200 day moving average is $128.27. The firm has a market cap of $596.98 million, a price-to-earnings ratio of -2.37 and a beta of 0.92. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.53 and a current ratio of 0.71. Mesa Laboratories, Inc. has a 52-week low of $83.68 and a 52-week high of $155.12.

Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. Research analysts predict that Mesa Laboratories, Inc. will post 8 EPS for the current year.

Mesa Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 16th. Stockholders of record on Friday, May 30th will be issued a dividend of $0.16 per share. The ex-dividend date is Friday, May 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.58%. Mesa Laboratories’s dividend payout ratio is currently -1.38%.

Insider Buying and Selling

In other news, CEO Gary M. Owens sold 21,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total value of $2,602,110.00. Following the completion of the transaction, the chief executive officer now owns 43,337 shares in the company, valued at $5,369,887.67. This trade represents a 32.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.40% of the stock is owned by insiders.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.